Back to Gilead Sciences

Gilead Sciences News

GILD

Gilead Issues $3B Senior Notes maturing 2028–2034

Gilead raises $3B through senior notes maturing 2028–2034 with coupons 4.25%–4.9%. Investor context on revenue mix, pipeline assets, and material risks.

GILD

GILD: Board Restructuring Linked to Merger

Arcellx directors and officers resign; Gilead executives to assume roles. Strategic tie to Gilead's CAR‑T oncology push and existing pipeline.

GILD

GILD: FDA Accepts Arcellx Anito-cel BLA

Feb 23, 2026 — FDA accepts Arcellx's BLA for anito-cel, advancing Gilead's CAR-T exposure; investors should monitor regulatory milestones and program risks.

GILD

Gilead to Acquire Arcellx at $115 + CVRs

Feb 23, 2026 — Gilead (GILD) agrees to acquire Arcellx for $115/share plus CVRs, adding a BLA‑filed CAR‑T program to its oncology pipeline.

GILD

GILD: Gilead Acquires Interius BioTherapeutics

Gilead (GILD) acquires Interius BioTherapeutics to expand its cell therapy and CAR-T portfolio — implications for oncology pipeline, revenues, and investor risk.

GILD

GILD Dividend Raised to $0.79 — Q4 2025

Gilead (GILD) board declares Q4 2025 quarterly dividend of $0.79/share, up from $0.77. Read analyst-focused context on cash drivers, pipeline and risks.

GILD

Gilead Advances HIV, Cell Therapy; Acquires Interius

Gilead (GILD) secures regulatory approvals and acquires Interius BioTherapeutics to bolster HIV and cell therapy pipelines; investor implications analyzed.

GILD

Gilead Advances HIV Prevention Portfolio

Gilead (GILD) strengthens HIV prevention with lenacapavir NDA, strategic partnerships and Biktarvy patent extension, reinforcing its PrEP and HIV franchise.

GILD

Gilead (GILD) Partners to Expand HIV PrEP

Gilead teams with the U.S. government and PEPFAR to expand global HIV PrEP delivery. Investor note: implications for the HIV franchise, lenacapavir NDA and revenue exposure.

GILD

Gilead Raises 2025 EPS & Sales Guidance

Gilead (GILD) raised its 2025 EPS and product sales guidance on Oct 30, 2025, supported by HIV product strength and U.S. sales concentration.

GILD

Moody’s Upgrades Gilead Outlook; A3 Affirmed

Moody’s affirms Gilead (GILD) A3 rating and upgrades outlook to positive on 2025-10-30. Key implications for credit profile, revenue drivers and investor risks.

GILD

GILD Q3 2025: Revenue Up, EPS $2.43

Gilead (GILD) Q3 2025 results: revenue +3% y/y, EPS $2.43. Key drivers, Biktarvy patent update, pipeline and risks for investors.

GILD

GILD Q3 2025: Revenue +3%, Patent Extension

Gilead (GILD) Q3 2025: revenues +3% YoY, Biktarvy patent extended to 2036, Moody's upgrades credit outlook, and board raises dividend.

GILD

Gilead Q3 2025: Revenue Up 3%, EPS $2.43

Gilead (GILD) Q3 2025 revenue rose 3% and EPS more than doubled to $2.43. Key drivers, product mix, patent context and investor risks explained.

GILD

GILD Q3: Revenue +3% & Dividend Hike

Gilead (GILD) Q3 revenue rose 3%; quarterly dividend increased and Biktarvy patent settlement extends exclusivity to 2036. What investors should know.

GILD

Gilead Q3 Updates: Patent Deal, Dividend & Outlook

Gilead (GILD) Q3 update: company reports results, patent settlement extending Biktarvy to 2036, dividend actions and management outlook for investors.

GILD

Gilead Raises 2025 EPS & Sales Guidance (GILD)

Gilead (GILD) raised full-year 2025 EPS and sales guidance, citing stronger HIV franchise and U.S. product sales. Outlook, risks, and pipeline context for investors.

GILD

Gilead Advances HIV and Oncology Portfolio

Gilead (GILD) secures approval for lenacapavir and acquires Interius BioTherapeutics, bolstering HIV and oncology pipelines; analysis of revenue, risks, and investor implications.

GILD

Gilead Expands HIV Prevention Efforts

Gilead (GILD) partners with U.S. agencies and acquires Interius BioTherapeutics to bolster HIV prevention and PrEP programs, complementing its lenacapavir work.

GILD

GILD: 2025 EPS Guidance Raised

Gilead raises 2025 EPS and product-sales guidance. Investors watch HIV franchise (Biktarvy), U.S. revenue concentration and pipeline catalysts.

GILD

Gilead Advances HIV PrEP Partnerships — GILD

Gilead (GILD) advances HIV prevention with lenacapavir NDA for once-yearly PrEP, strategic collaborations including Merck, and a HIV franchise led by Biktarvy.

GILD

Gilead Raises Q4 2025 Dividend to $0.79

Gilead Sciences (GILD) raises Q4 2025 dividend to $0.79 from $0.77. Investor-focused analysis, company context, and key risks.

GILD

Gilead Q3 2025: Revenue +3%, EPS $2.43

Gilead (GILD) Q3 2025 results: revenue up 3%, EPS rises to $2.43. Analysis of drivers, HIV franchise strength, pipeline and investor risks.

GILD

Gilead Raises 2025 EPS Guidance

Gilead (GILD) raises full-year 2025 EPS and product sales outlook. Investors should watch HIV franchise performance, product sales mix and regulatory risks.

GILD

GILD: Biktarvy Patent Exclusivity Extended to 2036

Gilead settles patent disputes, securing Biktarvy exclusivity through 2036 and blocking generics. Q1 2025 Biktarvy sales: $3.15B; HIV products core revenue.